Cargando…

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy

BACKGROUND: Opioid use disorder (OUD) in pregnancy is managed by medication-assisted treatment. Sublingual buprenorphine is one option, but subcutaneous extended-release buprenorphine (Sublocade®) is an alternate form administered in monthly injections. Through an extensive literature search, we did...

Descripción completa

Detalles Bibliográficos
Autores principales:	Towers, Craig V., Deisher, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382717/ https://www.ncbi.nlm.nih.gov/pubmed/32724686 http://dx.doi.org/10.1155/2020/3127676

Ejemplares similares

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
por: Ko, Jung-Woo, et al.
Publicado: (2020)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings
por: Boyett, Brent, et al.
Publicado: (2023)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
por: D'Agnone, Oscar
Publicado: (2019)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats
por: Zhang, Mingyun, et al.
Publicado: (2022)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice
por: DeTolla, L., et al.
Publicado: (2014)

Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report
por: Coish, Rebecca, et al.
Publicado: (2023)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post‐operative hypersensitivity in an incisional pain model in mice (Mus musculus)
por: Navarro, Kaela, et al.
Publicado: (2021)

Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine
por: Bormann, Nicholas L., et al.
Publicado: (2023)

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence
por: Hard, Bernadette
Publicado: (2021)

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product
por: Enomoto, Masataka, et al.
Publicado: (2017)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats
por: Guarnieri, M., et al.
Publicado: (2017)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2020)

BUPRENORPHINE ABUSE : A CASE REPORT
por: Nizamie, S. Haque, et al.
Publicado: (1990)

Synthetic Urines in a Buprenorphine Clinic
por: Embers, David M., et al.
Publicado: (2019)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus)
por: Fabian, Niora J., et al.
Publicado: (2023)

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
por: Marsden, John, et al.
Publicado: (2022)

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation
por: Lowry, Natalie, et al.
Publicado: (2022)

CASE REPORT OF SUBSTANCE DEPENDENCE WITH BUPRENORPHINE AND MEPHENTERMINE
por: Mendhekar, D.N., et al.
Publicado: (1999)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Correction to: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2021)

Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
por: Cowan, Alan, et al.
Publicado: (2015)

The use of buprenorphine/naloxone to treat borderline personality disorder: a case report
por: Hansen, Brenna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ulc38tda3kn2vla1gpj7q2ha0d